الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Ophthalmology>>15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide

15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide (Synonyms: 15ketoBimatoprost, 17phenyl trinor PGF2α ethyl amide)

رقم الكتالوجGC41937

Bimatoprost is the Allergan trade name for 17-phenyl trinor prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide), an F-series PG analog which has been approved for use as an ocular hypotensive drug.

Products are for research use only. Not for human use. We do not sell to patients.

15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide التركيب الكيميائي

Cas No.: 1163135-96-3

الحجم السعر المخزون الكميّة
1mg
94٫00
متوفر
5mg
425٫00
متوفر
10mg
754٫00
متوفر
25mg
1650٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Bimatoprost is the Allergan trade name for 17-phenyl trinor prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide), an F-series PG analog which has been approved for use as an ocular hypotensive drug. Oxidation of the C-15 hydroxyl group produces 15-keto-17-phenyl trinor PGF2α ethyl amide. 15-keto-17-phenyl trinor PGF2α ethyl amide is a potential metabolite of 17-phenyl trinor PGF2α ethyl amide when 17-phenyl trinor PGF2α ethyl amide is administered to intact animals. No pharmacological studies on 15-keto-17-phenyl trinor PGF2α ethyl amide have been reported.

مراجعات

Review for 15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 15-keto-17-phenyl trinor Prostaglandin F2α ethyl amide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.